BioMarin Projects Robust Revenue Growth in 2025

Published 1 hours agoBMRN

BioMarin Projects Robust Revenue Growth in 2025

BioMarin Pharmaceutical Inc. has announced ambitious revenue expectations for 2025, driven largely by the growth of its VOXZOGO product. The company forecasts total revenues between $3.1 billion and $3.2 billion for the year.

A significant portion of this revenue is expected to come from VOXZOGO, projected to contribute approximately $900 million to $950 million. As of the end of 2024, VOXZOGO was available in 47 countries, with BioMarin planning to extend this reach to over 60 countries by 2027. This international expansion is part of the strategy driving a compound annual growth rate exceeding 25% from 2023 to 2027 for VOXZOGO.

In addition to expanding VOXZOGO's market presence, BioMarin is implementing a $500 million cost transformation program aimed at achieving a 40% Non-GAAP Operating Margin by 2026. These efforts underscore the company's focus on enhancing operational efficiency and maximizing profitability. Reuters reported these developments following BioMarin's recent earnings announcement.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Universal Display Unveils 2025 Revenue Outlook and Strategic Developments

Universal Display Unveils 2025 Revenue Outlook and Strategic Developments

14 minutes agoOLED

Universal Display Corporation (UDC) recently outlined its financial expectations for 2025, projecting revenues between $640 million and $700 million. This projection indicates a careful approach amid the evolving landscape of the OLED industry. Additionally, UDC has declared a first-quarter 2025 cash dividend of $0.45 per share, payable on March 31, 2025, to shareholders on record as of March 17, 2025. In other developments, Universal Display is advancing its work on blue phosphorescent OLED (PHOLED) materials, which, despite taking longer than anticipated, are expected to reach commercialization in the coming months. This progress is significant for the OLED field. Moreover, UDC is restructuring its operations by closing its California-based OVJP center and setting up a new subsidiary, Universal Vapor Jet Corporation, in Singapore. This new entity will focus on commercializing its Organic Vapor Jet Printing technology, as reported by oled-info.com. These strategic moves illustrate UDC's dedication to innovation and growth within the OLED market. By enhancing its material development and restructuring its operations for efficient technology commercialization, UDC aims to solidify its position in the competitive OLED sector.

Amgen Projects Strong 2025 Revenue Growth with Expanding Product Pipeline

Amgen Projects Strong 2025 Revenue Growth with Expanding Product Pipeline

29 minutes agoAMGN

Amgen has recently projected robust revenue growth for 2025, forecasting total revenues between $34.3 billion and $35.7 billion with adjusted earnings per share ranging from $20.00 to $21.20. This positive outlook comes as the company continues to advance its extensive product pipeline and expand into new therapeutic areas. Key drivers influencing Amgen's anticipated growth include several innovative therapies. The cholesterol-lowering drug Repatha, osteoporosis treatment EVENITY, and severe asthma therapy TEZSPIRE are all expected to contribute significantly to Amgen’s revenue. Furthermore, the company's oncology portfolio, rare disease treatments, and the launch of new biosimilars should bolster earnings. According to longportapp.com, Amgen's biosimilar portfolio, in particular, experienced a 16% increase in 2024, contributing to its optimistic outlook. Amgen's strategic interests also reflect heavy investment in research and development, with a planned increase of approximately 15% in R&D spending year-over-year. The focus will be on advancing therapies like MariTide, an obesity treatment preparing for Phase 3 trials in early 2025, as mentioned by Amgen. Additionally, Amgen has announced a significant $900 million expansion of its biotech manufacturing facility in Ohio, a move that Reuters reports will generate 750 new jobs and increase its total investment in the region to over $1.4 billion.

Cerus Corporation Reports Strong 2024 Revenue Growth and Unveils 2025 Plans

Cerus Corporation Reports Strong 2024 Revenue Growth and Unveils 2025 Plans

44 minutes agoCERS

Cerus Corporation has unveiled its preliminary financial performance for 2024, highlighting impressive growth in product revenue. According to the company's official statement, they recorded a full-year product revenue of $180.3 million, which marks a 15% increase compared to the previous year. Notably, their INTERCEPT Fibrinogen Complex (IFC) revenue soared to $9.2 million, a 42% rise from 2023, as cited by ir.cerus.com. Looking ahead, Cerus has provided revenue guidance for 2025, forecasting product revenues between $194 million and $200 million, representing an 8% to 11% increase year-over-year. For IFC, they anticipate revenues to range from $12 million to $15 million. Strategies moving into 2025 include the introduction of their LED Illuminator in Europe, a move aimed at broadening their market reach and product line. In addition to these financial developments, Cerus Corporation has successfully maintained positive operating cash flows for the fourth consecutive quarter, showcasing robust financial health and solid operational capabilities, as noted by Nasdaq.com. This strong financial performance is coupled with strategic initiatives that underline the company's commitment to advancing growth and innovation in the blood safety industry.

Workiva Projects 20% Subscription Revenue Growth by 2025 Despite Market Challenges

Workiva Projects 20% Subscription Revenue Growth by 2025 Despite Market Challenges

59 minutes agoWK

Workiva Inc. has reaffirmed its goal for a 20% increase in subscription revenue by 2025, even amid a cautious buying environment. The company remains firm in its strategic growth targets, highlighting its role as a reliable integrated reporting platform aimed at helping customers manage risk and bolster performance. In terms of financial specifics, Workiva expects to achieve a total revenue ranging between $864 million and $868 million for 2025. Their non-GAAP operating margin is projected to be between 5% and 5.5%, reflecting enhanced operational productivity compared to the previous year. Additionally, the company anticipates a free cash flow margin of about 12%. Notably, in the fourth quarter of 2024, Workiva saw a 22% increase in subscription and support revenue, leading to a total revenue of $200 million, marking a 20% growth from the previous year, as reported by their investor communications. Despite the unpredictable business landscape shaped by policy and geopolitical issues, Workiva is optimistic about its future performance. The company has positioned itself strategically to navigate these challenges, aiming to deliver continued growth and value to its customers, a sentiment echoed in reports by sources including itiger.com.